Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide
2019 San Antonio Breast Cancer SymposiumNadine M. Tung, MD, of Beth Israel Deaconess Medical Center, discusses cisplatin vs doxorubicin/cyclophosphamide (AC) as neoadjuvant treatment in BRCA-mutation carriers with HER2-negative breast cancer. Although cisplatin as a single agent shows activity in this setting, the pathologic complete response with this agent alone is not higher than that with standard AC chemotherapy (Abstract GS6-03).
Related Videos
Tari A. King, MD, on Molecular Differences Between Primary and Metastatic Breast Tumors
Tari A. King, MD, of Brigham and Women’s Hospital and Dana-Farber/ Brigham and Women’s Cancer Center, discusses retrospective findings from the AURORA U.S. Network on molecul...
Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
Ivana Sestak, PhD, of Queen Mary University of London and the Centre for Cancer Prevention, discusses study findings that confirm the prognostic ability of the Clinical Treat...
Terry P. Mamounas, MD, MPH, on Extending Letrozole Treatment in Hormone Receptor–Positive Breast Cancer
Terry P. Mamounas, MD, MPH, of Orlando Health UF Health Cancer Center, discusses 10-year results from NRG Oncology/NSABP B-42, which showed that, for postmenopausal women wit...
Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer
Milan Radovich, PhD, of Indiana University School of Medicine, discusses trial findings that show patients with triple-negative breast cancer who are at high risk of relapse ...
Gerardo Antonio Umanzor Funez, MD, on Metastatic Breast Cancer: Comparing IV and Oral Formulations of Paclitaxel
Gerardo Antonio Umanzor Funez, MD, of Liga Contra El Cáncer, discusses phase III findings on intravenous (IV) paclitaxel and oral paclitaxel plus encequidar (a novel P-gp inh...
